Shareholder Derivative

SAN FRANCISCO – Directors propped up the share price of Dynavax Technologies by misrepresenting prospects of its Heplisav hepatitis B drug, and the share price dropped by 69% when the truth came out, shareholders claim in a derivative complaint.

Exit mobile version